UPSHER-SMITH AND PARENT COMPANY BORA PHARMACEUTICALS HOST IOWA GOVERNOR KIM REYNOLDS TO DISCUSS U.S. SUPPLY CHAIN AND REGIONAL COLLABORATION

UPSHER-SMITH AND PARENT COMPANY BORA PHARMACEUTICALS HOST IOWA GOVERNOR KIM REYNOLDS TO DISCUSS U.S. SUPPLY CHAIN AND REGIONAL COLLABORATION

MAPLE GROVE, Minn., July 22, 2025 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a Midwest-based pharmaceutical company focused on specialty brands and generics, currently part of Bora Group (TWSE: 6472), a global leader in pharmaceutical manufacturing, today welcomed Iowa Governor Kim Reynolds to their Maple Grove, Minnesota headquarters for a roundtable discussion and facility tour focused on advancing pharmaceutical innovation and exploring opportunities for regional collaboration.

As part of the Governor's domestic mission trip, Governor Reynolds met with leaders from Upsher-Smith and Bora Group to discuss onshoring pharmaceutical manufacturing, strengthening supply chain integration across the Midwest, and expanding contract development and manufacturing.

"This is a great example of how Iowa can lead the nation in revitalizing domestic manufacturing and strengthening critical industries," said Governor Kim Reynolds. "Upsher-Smith and Bora Group are investing in people, innovation, and infrastructure; the very pillars of the high-value growth we're driving in Iowa. By fostering regional partnerships and expanding U.S. supply chains, we're not only advancing healthcare - we're creating jobs, fueling economic growth, and enhancing long-term competitiveness for our states."

The visit began with a tour of the Maple Grove manufacturing facility and a forward-looking discussion about growing domestic manufacturing and Contract Development and Manufacturing Organization (CDMO) opportunities, both critical components of a resilient pharmaceutical supply chain.

During the roundtable, executives from Upsher-Smith highlighted the Company's branded and generic product portfolio and its impact on patient care through high-quality, specialty generic medications, including treatments for pediatric rare diseases. Bora Group leaders shared insights into the company's integrated global network, pharmaceutical development and manufacturing capabilities, and vision for expanding CDMO partnerships in the U.S.

"Bora is deeply committed to strengthening pharmaceutical manufacturing here in the U.S.," said Dennis Hall, Vice President and General Manager, Bora Pharmaceuticals. "As a global CDMO with a growing domestic footprint, we see tremendous opportunity for investment, innovation, and collaboration. We appreciate leaders like Governor Reynolds who understand the critical role of a resilient, U.S.-based supply chain in ensuring patients have consistent access to essential medicines."

Discussions also focused on Bora's robust domestic production capabilities and ongoing commitment to U.S. operations. To date, the company has invested hundreds of millions of dollars in domestic infrastructure. In 2023, Upsher-Smith announced the opening of its new, 270,000 square-foot, state-of-the-art greenfield manufacturing facility. The Maple Grove facility offers fully up-to-date packaging and serialization capabilities and supports contract manufacturing for third parties.

About Upsher-Smith
Upsher-Smith Laboratories, LLC, now a member of Bora Group, is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. We bring generics and brands to a wide array of customers, always backed by our attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.

About Bora Group
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life. By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit www.bora-corp.com.

About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit www.boracdmo.com.  

About the Iowa Economic Development Authority
The Iowa Economic Development Authority (IEDA) strengthens the state's economic foundation by fostering business growth, community development, and vibrant places to live and work. IEDA administers programs designed to attract and retain businesses, encourage innovation, support entrepreneurs, and promote Iowa as a premier destination for investment, travel and talent. With a focus on collaboration and long-term impact, IEDA works with public and private partners to advance economic opportunities and improve quality of life for all Iowans. Learn more at www.iowaeda.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/upsher-smith-and-parent-company-bora-pharmaceuticals-host-iowa-governor-kim-reynolds-to-discuss-us-supply-chain-and-regional-collaboration-302510746.html

SOURCE Upsher-Smith Laboratories, LLC